Innoviva (INVA) Cash from Financing Activities (2010 - 2026)
Innoviva (INVA) posted Cash from Financing Activities of -$20.1 million for Q1 2026, down 264.16% on a QoQ basis from $12.3 million in Q3 2025, and down 11108.74% year-over-year from N/an in Q1 2025.
Innoviva (INVA) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Innoviva's Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$20.1 million for Q1 2026.
- Quarterly Cash from Financing Activities fell 11108.74% year-over-year to -$20.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.4 million (up 77.05% YoY) and the FY2025 annual result came in at $8.6 million, up 163.56% from the prior year.
- Cash from Financing Activities was -$20.1 million for Q1 2026 at Innoviva, down from $12.3 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $60.3 million in Q1 2022 and bottomed at -$157.2 million in Q3 2023.
- A 5-year average of -$25.6 million and a median of -$9.2 million in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities soared 383.11% — and 2026, when it tumbled 11108.74%.
- Innoviva's Cash from Financing Activities stood at -$45.6 million in 2022, then sank by 245.1% to -$157.2 million in 2023, then jumped by 91.08% to -$14.0 million in 2024, then soared by 187.49% to $12.3 million in 2025, then plunged by 264.16% to -$20.1 million in 2026.
- Business Quant data shows INVA's Cash from Financing Activities at -$20.1 million in Q1 2026, $12.3 million in Q3 2025, and $1.2 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Innoviva | 1.57 Bn | 969.11 Mn | 75.83 Mn | -20.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.15 Mn |
| Mar 31, 2026 | -20.15 Mn |
| Sep 30, 2025 | 12.27 Mn |
| Sep 30, 2025 | 12.27 Mn |
| Jun 30, 2025 | 1.25 Mn |
| Jun 30, 2025 | 1.25 Mn |
| Mar 31, 2025 | 183,000.00 |
| Mar 31, 2025 | 183,000.00 |
| Sep 30, 2024 | -14.03 Mn |
| Sep 30, 2024 | -14.03 Mn |
| Jun 30, 2024 | -5.07 Mn |
| Jun 30, 2024 | -5.07 Mn |
| Mar 31, 2024 | -9.17 Mn |
| Mar 31, 2024 | -9.17 Mn |
| Sep 30, 2023 | -157.25 Mn |
| Sep 30, 2023 | -157.25 Mn |
| Jun 30, 2023 | -9.21 Mn |
| Jun 30, 2023 | -9.21 Mn |
| Mar 31, 2023 | -136.96 Mn |
| Mar 31, 2023 | -136.96 Mn |